Literature DB >> 15187240

Nailfold videocapillaroscopy in primary antiphospholipid syndrome (PAPS).

J L P Vaz1, M A A Dancour, D A Bottino, E Bouskela.   

Abstract

OBJECTIVES: To evaluate microcirculatory changes (functional and morphological) in primary antiphospholipid syndrome (PAPS) patients.
METHODS: Thirty-one patients were examined using nailfold videocapillaroscopy (18 PAPS patients and 13 healthy subjects). The patients were subdivided into two subgroups, with lupus anticoagulant (n = 8) and with anticardiolipin (n = 10) antibodies. Capillary morphology was determined; diameters ( micro m) and functional capillary density (FCD, number capillaries/mm2) were measured in control conditions. Blood flow velocity (CBFV, mm/s) was also evaluated at rest and after release of 60 s arterial occlusion.
RESULTS: The percentage of subjects with at least one morphological alteration in the observed capillaries was 77.8% for patients and 21.3% for healthy subjects. Capillary diameters ( microm) [afferent (AD), apical (APD) and efferent (ED)] were significantly smaller (mean +/- s.d.: AD-PAPS, 7.4 +/- 2.1; control, 9.1 +/- 2.6, P = 0.063; APD-PAPS, 11.6 +/- 2.3; control, 14.4 +/- 3.8, P = 0.015; ED-PAPS, 8.4 +/- 2.0; control, 10.9 +/- 3.2, P = 0.011) in PAPS patients compared with controls. FCD (PAPS, 8.5 +/- 3.2; control, 8.3 +/- 2.9, P +/- 0.862), mean resting CBFV (PAPS, 0.73 +/- 0.31; control, 0.88 +/- 0.41, P = 0.278), mean peak CBFV after occlusion (PAPS, 1.07 +/- 0.52; control, 1.59 +/- 0.91, P = 0.063) and mean time (s) to reach it (PAPS, 5.2 +/- 1.7; control, 4.6 +/- 1.8, P = 0.101) were not statistically different between the two groups.
CONCLUSION: Our results suggest that nailfold capillary morphology is altered in patients with PAPS, but these changes could not be correlated to impairment of functional parameters.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15187240     DOI: 10.1093/rheumatology/keh233

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  7 in total

1.  Nailfold videocapillaroscopy in patients with systemic lupus erythematosus.

Authors:  M A A Dancour; J L P Vaz; D A Bottino; E Bouskela
Journal:  Rheumatol Int       Date:  2005-09-23       Impact factor: 2.631

Review 2.  [Capillaroscopy and rheumatic diseases: state of the art].

Authors:  M Cutolo; A Sulli; M E Secchi; C Pizzorni
Journal:  Z Rheumatol       Date:  2006-07       Impact factor: 1.372

Review 3.  Renal manifestations of the antiphospholipid syndrome.

Authors:  David D'Cruz
Journal:  Curr Rheumatol Rep       Date:  2009-02       Impact factor: 4.592

Review 4.  The role of capillaroscopy in differentiation of primary and secondary Raynaud's phenomenon in rheumatic diseases: a review of the literature and two case reports.

Authors:  Sevdalina Nikolova Lambova; Ulf Müller-Ladner
Journal:  Rheumatol Int       Date:  2009-06-23       Impact factor: 2.631

5.  Antiphospholipid antibodies and anticoagulant therapy: capillaroscopic findings.

Authors:  Giorgia Ferrari; Emanuele Gotelli; Vanessa Smith; Maurizio Cutolo; Sabrina Paolino; Giampaola Pesce; Luca Nanni; Barbara Maria Colombo; Greta Pacini; Carlotta Schenone; Carmen Pizzorni; Alberto Sulli
Journal:  Arthritis Res Ther       Date:  2021-06-27       Impact factor: 5.156

6.  NEMO score in nailfold videocapillaroscopy is a good tool to assess both steady state levels and overtime changes of disease activity in patients with systemic sclerosis: a comparison with the proposed composite indices for this disease status entity.

Authors:  Francesca Pignataro; Wanda Maglione; Antonina Minniti; Domenico Sambataro; Gianluca Sambataro; Francesco Campanaro; Gabriele Valentini; Claudio Vitali; Nicoletta Del Papa
Journal:  Arthritis Res Ther       Date:  2019-11-29       Impact factor: 5.156

7.  High NEMO score values in nailfold videocapillaroscopy are associated with the subsequent development of ischaemic digital ulcers in patients with systemic sclerosis.

Authors:  Nicoletta Del Papa; Francesca Pignataro; Wanda Maglione; Antonina Minniti; Domenico Sambataro; Gianluca Sambataro; Gabriele Valentini; Roberto Caporali; Claudio Vitali
Journal:  Arthritis Res Ther       Date:  2020-10-13       Impact factor: 5.156

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.